CHECK MY PAGE FOR MORE INFO, ILL BE UPLOADING VIDEOS DAILY OR WHEN POSSIBLE, SUBSCRIBE AND SEND THE INFO TO AS MANY PEOPLE AS POSSIBLE.
VIEW THE PATENT APPLICATIONS HERE:
Patent Application for H1N1 Virus: US20080069821A1
Patent Application Link:
http://www.google.com/patents?id=EGSo...
Related US Patent #5,698,433 (1997 version):
METHOD FOR PRODUCING INFLUENZA VIRUS AND VACCINE (assignee: Baxter)
What is claimed is:
1. An isolated polypeptide, wherein said polypeptide is selected from the group consisting of: a) a polypeptide comprising the amino acid sequence encoded by the nucleotide sequence as shown in any one of SEQ ID NOS:21-26 or 33-38 or 45; b) a polypeptide comprising the amino acid sequence as shown in any one of SEQ ID NOS:27-32 or 39-44; c) the mature form of a polypeptide comprising the amino acid sequence as shown in any one of SEQ ID NOS: 27-32 or 39-44; d) a polypeptide comprising an amino acid sequence encoded by a polynucleotide which hybridizes under highly stringent conditions to a polynucleotide comprising a nucleotide sequence encoding (a) (b) or (c); and e) a polypeptide comprising an amino acid sequence having at least 90% sequence identity to the polypeptide of (b).
2. An immunogenic composition comprising an immunologically effective amount of at least one polypeptide of claim 1.
3. An isolated antibody that specifically binds the polypeptide of claim 1.
4. A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual an immunologically effective amount of the polypeptide of claim 1 in a physiologically acceptable carrier.
5. A recombinant influenza virus comprising the polypeptide of claim 1.
6. An immunogenic composition comprising an immunologically effective amount of the recombinant influenza virus of claim 5.
7. A method for stimulating the immune system of an individual to produce a protective immune response against influenza virus, the method comprising administering to the individual an immunologically effective amount of the recombinant influenza virus of claim 5 in a physiologically acceptable carrier.
8. An isolated polynucleotide, wherein said polynucleotide is selected from the group consisting of: a) a polynucleotide comprising the nucleotide sequence as shown in any one of SEQ ID NOS: 21-26 or 33-38 or 45, or a complementary sequence thereof; b) a polynucleotide comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequence as shown in any one of SEQ ID NOS: 27-32 or 39-44, or a complementary nucleotide sequence thereof; c) a polynucleotide which hybridizes under highly stringent conditions over substantially the entire length of the polynucleotide of (a); and d) a polynucleotide comprising a nucleotide sequence having at least 98% sequence identity to the polynucleotide of (a).
9. An immunogenic composition comprising at least one polynucleotide of claim 8.
10. A cell comprising at least one polynucleotide of claim 8.
11. A vector comprising the polynucleotide of claim 8.
12. The vector of claim 11, wherein the vector is a plasmid, a cosmid, a phage, a virus, or a fragment of a virus.
13. The vector of claim 12, wherein the vector is an expression vector.
14. A cell comprising the vector of claim 13.
15. An influenza virus comprising one or more polynucleotides of claim 8.
16. The virus of claim 15, wherein the virus is a reassortant virus.
17. A 6:2 reassortant influenza virus, wherein said virus comprises 6 internal genome segments from A/Ann Arbor/6/60 and 2 genome segments that encode an HA and/or a NA polypeptide selected from the group consisting of: the polypeptides of SEQ ID NOS:27-32, and 39-44.
18. A method of producing a reassortant influenza virus, the method comprising: culturing the cell of claim 14 in a suitable culture medium under conditions permitting expression of said polynucleotide; and, isolating the reassortant influenza virus from a cell population comprising said cell or the medium.
19. An immunogenic composition comprising an immunologically effective amount of the reassortant influenza virus of claim 17.
There are 19 more claims which cannot fit into this description. Please check the first link above for the rest.
Loading...
4:56
Medical Doctor Retracts H1N1 Vaccine Advice After Reading Insertby mark71j598 views
Above information should be better commented by a specialized medical doctor, as the patent wording could be just confusing us as non specialists: The virus description could be necessary for the patents claims. I could not be sure
ALCOLOR 2 years ago